Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company): 4 sponsored US clinical trials, 1 recruiting.
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Inflammatory Bowel Diseases, with 2 trials.
Upper-quartile sponsor footprint
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
NCT05291689
Study of MORF 057 to Evaluate Single and Multi Ascending Doses in Healthy Volunteers
NCT04580745
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) pipeline
1 recruiting of 4 indexed (25% open); 2 completed (50%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Inflammatory Bowel Diseases (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company): open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) page
4 registered trials is a research-attention snapshot, not an endorsement of Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) or any single study.
- 1 of Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Inflammatory Bowel Diseases is the condition Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Inflammatory Bowel Diseases trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) pipeline card: 4 registered trials from official public datasets.Report a data error.